drugset

drugset / Trial / NCT03907540

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

NCT03907540 ↗

Phase 1 Completed 5 enrolled Kadmon Corporation, LLC Quotient Sciences · collab

Non-randomizedSequentialOpen-labelBasic science

Summary

Human, absorption, metabolism and excretion study of belumosudil (KD025)

Timeline

Start: 2019-04-05
Primary completion: 2019-05-20
Completion: 2019-05-20

Publications

Background Schueller O, Skucas E, Regev G, Shaw I, Singh N, Sanghvi M, Croft M, Lohmer L, Alabanza A, Patel J. Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14 C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study. Clin Pharmacol Drug Dev. 2022 Jul;11(7):786-794. doi: 10.1002/cpdd.1085. Epub 2022 Mar 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belumosudil	Small molecule	100 ug	Oral
Subject	Belumosudil	Small molecule	200 mg	Oral

Indications